UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

High-dose chemotherapy for recurrent ovarian germ cell tumors

Journal of clinical oncology, 2015-01, Vol.33 (2), p.226-227

2015

Volltextzugriff (PDF)

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Oncotarget, 2016-08, Vol.7 (35), p.56491-56500

2016

Volltextzugriff (PDF)

Impact of dialysis requirement on outcomes in tumor lysis syndrome

Nephrology (Carlton, Vic.), 2017-01, Vol.22 (1), p.85-88

2017

Volltextzugriff (PDF)

Adjuvant therapy for endometrial cancer

Journal of Gynecologic Oncology, 2014, 25(2), , pp.136-147

2014

Volltextzugriff (PDF)

Severe Bradycardia Caused by a Single Dose of Lithium

Internal Medicine, 2013, Vol.52(7), pp.767-769

2013

Volltextzugriff (PDF)

Clostridium septicum aortitis in a patient with extensive atheromatous disease of the aorta

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012-12, Vol.18 (6), p.948-950

2012

Volltextzugriff (PDF)

Patient satisfaction and resident postgraduate year status

International journal of health care quality assurance, 2014-01, Vol.27 (3), p.182-189

2014

Volltextzugriff (PDF)

CTNI-76. EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394) IN RECURRENT, PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST)

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v95-v95

2023

Volltextzugriff (PDF)

Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3006-3006

2023

Volltextzugriff (PDF)

Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3106-3106

2023

Volltextzugriff (PDF)

TRLS-02. SAFETY AND EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394; PLX8394) IN CHILDREN AND ADULTS WITH RECURRENT, BRAF-ALTERED PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST)

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Volltextzugriff (PDF)

Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9049-9049

2014

Volltextzugriff (PDF)

High-dose chemotherapy (HDCT) for recurrent ovarian germ cell tumors (OGCT): Indiana University (IU) experience

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5547-5547

2014

Volltextzugriff (PDF)

Adjuvant therapy for endometrial cancer

Journal of gynecologic oncology, 2014-04, Vol.25 (2), p.136-147

2014

Volltextzugriff (PDF)

A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients (pts) with incurable platinum refractory germ cell tumors (GCT)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4579-TPS4579

2016

Volltextzugriff (PDF)

Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4520-4520

2017

Volltextzugriff (PDF)

Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT202-CT202

2022

Volltextzugriff (PDF)

Risk stratification of clinical stage I (CSI) non-seminomatous germ cell testicular tumors (NSGCT): A retrospective analysis of experience at Indiana University (IU)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e16052-e16052

2016

Volltextzugriff (PDF)

Next generation sequencing in community oncology practice: Beneficial or economical burden?

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.102-102

2017

Volltextzugriff (PDF)

Abstract W P421: Trend in Concurrent Hospitalization for Moyamoya and Sickle Cell Disease: An Analysis of Nationwide Inpatient Sample Data

Stroke (1970), 2015-02, Vol.46 (suppl_1)

2015

Volltextzugriff (PDF)

Older Age and Co-Morbidities Do Not Predict Incidence of Dose Limiting Toxicities in Lymphoma Phase I Trials At MSKCC

Blood, 2011-11, Vol.118 (21), p.3145-3145

2011

Volltextzugriff (PDF)

Feasibility of tumor genome sequencing: single center experience

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e22131-e22131

2015

Volltextzugriff (PDF)

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT028-CT028

2023

Volltextzugriff (PDF)

Tumor necrosis factor inhibitor-induced serositis

American journal of therapeutics, 2014-09, Vol.21 (5), p.e166

2014

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(7)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Male
(6)
Middle Aged
(5)
Female
(4)
Adult
(3)
Aged
(3)
Oncology
(3)
Treatment Outcome
(3)
Adjuvant Therapy
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Early Stage
(2)
Endometrial Cancer
(2)
Locally Advanced
(2)
Medicine
(2)
Risk Stratification
(2)
Acute Kidney Injury
(1)
Acute Kidney Injury - Diagnosis
(1)
Acute Kidney Injury - Etiology
(1)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

High-dose chemotherapy for recurrent ovarian germ cell tumors

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Impact of dialysis requirement on outcomes in tumor lysis syndrome

Adjuvant therapy for endometrial cancer

Severe Bradycardia Caused by a Single Dose of Lithium

Clostridium septicum aortitis in a patient with extensive atheromatous disease of the aorta

Patient satisfaction and resident postgraduate year status

CTNI-76. EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394) IN RECURRENT, PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST)

Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study

Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results

TRLS-02. SAFETY AND EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394; PLX8394) IN CHILDREN AND ADULTS WITH RECURRENT, BRAF-ALTERED PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST)

Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings

High-dose chemotherapy (HDCT) for recurrent ovarian germ cell tumors (OGCT): Indiana University (IU) experience

Adjuvant therapy for endometrial cancer

A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients (pts) with incurable platinum refractory germ cell tumors (GCT)

Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT)

Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress)

Risk stratification of clinical stage I (CSI) non-seminomatous germ cell testicular tumors (NSGCT): A retrospective analysis of experience at Indiana University (IU)

Next generation sequencing in community oncology practice: Beneficial or economical burden?

Abstract W P421: Trend in Concurrent Hospitalization for Moyamoya and Sickle Cell Disease: An Analysis of Nationwide Inpatient Sample Data

Older Age and Co-Morbidities Do Not Predict Incidence of Dose Limiting Toxicities in Lymphoma Phase I Trials At MSKCC

Feasibility of tumor genome sequencing: single center experience

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Tumor necrosis factor inhibitor-induced serositis

Suchergebnisse filtern